Cognitive Rehabilitation in Sickle Cell Disease
Primary Purpose
Sickle Cell Disease, Cognitive Impairment
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Cogmed
Sponsored by
About this trial
This is an interventional treatment trial for Sickle Cell Disease focused on measuring sickle cell disease, pediatric, learning disability, cognitive impairment, memory, attention, Children with sickle cell disease
Eligibility Criteria
Inclusion Criteria:
- 1) Children with a diagnosis of SCD (all genotypes)
- 2) a T-score ≥75th percentile on either the Metacognition or Executive Composite of the BRIEF; and/or
- 3) a standard score ≥1 standard deviation below the mean (<90) on the tasks of executive function or WM from the Cogstate (mean=100; SD=10)
Exclusion Criteria:
- 1) Estimated IQ ≤ 75), or motor, visual, or auditory handicap that prevents computer use;
- 2) a diagnosis of depression or a pervasive developmental disorder (by history);
- 3) clinical stroke (via record medical history); or
- 4) non-English fluency.
Sites / Locations
- Duke Child and Family Study Center
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
Cogmed
Waitlist
Arm Description
These children are enrolled in the Cogmed intervention.
These children are enrolled in a waitlist condition, after which they will be offered the opportunity to complete the intervention.
Outcomes
Primary Outcome Measures
Feasibility
Feasibility is defined as 75% of subjects completing 80% of the training program.
Secondary Outcome Measures
Efficacy
Efficacy will be defined by participant performance on cognitive outcome measures including executive functioning outcomes from the Cogstate.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01793740
Brief Title
Cognitive Rehabilitation in Sickle Cell Disease
Official Title
Cognitive Rehabilitation of Children With Sickle Cell Disease: A Pilot Study
Study Type
Interventional
2. Study Status
Record Verification Date
August 2014
Overall Recruitment Status
Completed
Study Start Date
October 2012 (undefined)
Primary Completion Date
July 2014 (Actual)
Study Completion Date
July 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Duke University
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The majority of school-age children with sickle cell disease (SCD) experience neurocognitive deficits, even in the absence of stroke. In particular, deficits in attention and working memory have emerged as two of the most common neurocognitive sequelae of SCD. Thus, the goal of the present proposal is to address feasibility and compliance of a novel computerized cognitive training program, Cogmed. Pilot data will also be collected to establish preliminary efficacy. Twenty-four children meeting initial age and diagnostic criteria will be identified and approached about participation by their attending physician during regularly-scheduled SCD clinic visits. Baseline assessments will include a brief measure of intellectual functioning, a brief cognitive testing battery evaluating processing speed and working memory, in addition to questionnaires regarding behavior and quality of life. Children will then be randomized to the computerized CT program Cogmed (n=12) or a waitlist control (n=12). Participants enrolled in the computerized CT program will be asked to complete 25-sessions of Cogmed over a five to eight week period (3 to 5 sessions per week). Following completion of the program, children and their parents will be asked to return to clinic for a follow-up visit. After a five to eight-week waiting period, children in the waitlist condition will also be asked to return to clinic for a second visit. Following this assessment, participants initially enrolled in the waitlist will be offered an opportunity to participant in the intervention. If interested, they will follow the same intervention protocol described above. These children will return to clinic for a third visit following completion of the intervention. Compliance rate and its confidence interval will be calculated for the overall study population. A t-test for binomial proportion with continuity correction will be used to examine whether the compliance rate is lower than the target. Participants' change in criterion outcomes will be evaluated (i.e., those neurocognitive measures such as attention, executive functioning and working memory, that are most closely related to the trained tasks).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sickle Cell Disease, Cognitive Impairment
Keywords
sickle cell disease, pediatric, learning disability, cognitive impairment, memory, attention, Children with sickle cell disease
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
18 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Cogmed
Arm Type
Experimental
Arm Description
These children are enrolled in the Cogmed intervention.
Arm Title
Waitlist
Arm Type
No Intervention
Arm Description
These children are enrolled in a waitlist condition, after which they will be offered the opportunity to complete the intervention.
Intervention Type
Behavioral
Intervention Name(s)
Cogmed
Other Intervention Name(s)
Cogmed computerized cognitive training
Intervention Description
Computer based program that aims to improve children's memory, attention, and processing speed.
Primary Outcome Measure Information:
Title
Feasibility
Description
Feasibility is defined as 75% of subjects completing 80% of the training program.
Time Frame
Post-study - Baseline to Post-Intervention, approximately 5 to 8-weeks after baseline assessment
Secondary Outcome Measure Information:
Title
Efficacy
Description
Efficacy will be defined by participant performance on cognitive outcome measures including executive functioning outcomes from the Cogstate.
Time Frame
Baseline to Post-Intervention, approximately 5 to 8-weeks after baseline assessment
Other Pre-specified Outcome Measures:
Title
Acceptance
Description
Acceptance is defined by 50% of those approached are able to participate/consent to the study.
Time Frame
After the recruitment period has been completed (approximately 2-years)
10. Eligibility
Sex
All
Minimum Age & Unit of Time
8 Years
Maximum Age & Unit of Time
16 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
1) Children with a diagnosis of SCD (all genotypes)
2) a T-score ≥75th percentile on either the Metacognition or Executive Composite of the BRIEF; and/or
3) a standard score ≥1 standard deviation below the mean (<90) on the tasks of executive function or WM from the Cogstate (mean=100; SD=10)
Exclusion Criteria:
1) Estimated IQ ≤ 75), or motor, visual, or auditory handicap that prevents computer use;
2) a diagnosis of depression or a pervasive developmental disorder (by history);
3) clinical stroke (via record medical history); or
4) non-English fluency.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Melanie J Bonner, PhD
Organizational Affiliation
Duke University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Duke Child and Family Study Center
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27705
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Cognitive Rehabilitation in Sickle Cell Disease
We'll reach out to this number within 24 hrs